Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena.

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Hysterosalpingo-foam sonography, a less painful procedure for tubal patency testing during fertility workup compared with (serial) hysterosalpingography:

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment Javier Domingo, M.D., Vicente.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates Liang Zhou, M.D., Rong Li, M.D., Ph.D., Rong.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.

José Bellver, M. D. , Marco A. B. Melo, M. D. , Ernesto Bosch, M. D

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Michael M. Alper, M.D. Fertility and Sterility

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

Hysterosalpingo-foam sonography, a less painful procedure for tubal patency testing during fertility workup compared with (serial) hysterosalpingography:

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Prospective evaluation of luteal phase length and natural fertility

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro.

Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study Ahmet Erdem, M.D., Mehmet Erdem,

Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to.

Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review Carlo Alviggi, M.D., Ph.D., Alessandro Conforti,

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Fertility and Sterility

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Roberto Ensenat-Waser, Ph. D. , Antonio Pellicer, M. D. , Ph. D

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

A case of ovarian hyperstimulation syndrome associated with the methylenetetrahydrofolate reductase mutation gene Filippo Ferrara, M.D., Francesco Meli,

Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated.

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Sedigheh Borna, M.D., Azita Nasery, M.D. Fertility and Sterility

Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Current evaluation of amenorrhea

Fertility and Sterility

Combined use of uterine artery embolization and local methotrexate injection in interstitial ectopic pregnancies with poor prognosis Gemma Tamarit, M.D.,

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories Melissa C. Yih, M.D.,

Diane De Neubourg, M. D. , Kathelijne Mangelschots, B. Sc

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome Ernesto Bosch,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review.

Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:

In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study Carmen Rubio,

Ernesto Bosch, M. D. , Elena Labarta, M. D

Presentation transcript:

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena Labarta, M.D., Juana Crespo, M.D., Carlos Simón, M.D., José Remohí, M.D., Antonio Pellicer, M.D. Fertility and Sterility Volume 95, Issue 3, Pages 1031-1036 (March 2011) DOI: 10.1016/j.fertnstert.2010.10.021 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 1 (A) CONSORT statement flow diagram of patients aged ≤35 years. (B) CONSORT statement flow diagram of patients aged between 36 and 39 years. CONSORT = Consolidated Standards of Reporting Trials; OHSS = ovarian hyperstimulation syndrome. Fertility and Sterility 2011 95, 1031-1036DOI: (10.1016/j.fertnstert.2010.10.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Comparative cycle outcome of rFSH + rLH administration in relation to rFSH alone in patients aged ≤35 years (left) and 36 to 39 years (right). ITT = intention-to-treat analysis; PR = pregnancy rate. Fertility and Sterility 2011 95, 1031-1036DOI: (10.1016/j.fertnstert.2010.10.021) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions